Industry Reports

Bristol-Myers Squibb Company has reported results for the third quarter of 2013 highlighted by the strong performance of key marketed products such as Yervoy, Orencia and Sprycel, the presentation of important clinical data for its immuno-oncology pipeline, and the...

Abbott today announced financial results for the third quarter ended Sept. 30, 2013. Third-quarter 2013 worldwide sales of $5.4 billion increased 4.3 percent on an operational basis, with strong performance in Diagnostics and Medical Devices. ...

Adocia , a biotechnology company specialized in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, announces today its Q1 2013 revenues. Detail of the Q1 2013 revenues In thousands of euros...

Bristol-Myers Squibb Company (NYSE: BMY) reported financial results for the first quarter of 2013, and confirmed GAAP EPS and non-GAAP EPS guidance ranges for 2013. Bristol-Myers Squibb posted first quarter 2013 net sales of $3.8 billion, a decrease...

Abbott announced financial results for the first quarter ended March 31, 2013. Worldwide sales of nearly $5.4 billion increased 3.5 percent on an operational basis, consistent with previous guidance, driven by 9.0 percent operational sales growth in Nutrition...

Bristol-Myers Squibb Company will announce results for the first quarter of 2013 on Thursday April 25 2013. During a conference call at 10:30 a.m. EDT on April 25 company executives will review financial information and will address inquiries...

Adocia, a biotechnology company specialized in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, announces today its financial results for 2012. The financial statements were approved by the board of directors of...